Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Prevalence and management of lower urinary tract symptoms in methamphetamine abusers: an under-recognized clinical identity.

Koo KC, Lee DH, Kim JH, Rha KH, Chung BH, Hong SJ, Mah SY.

J Urol. 2014 Mar;191(3):722-6. doi: 10.1016/j.juro.2013.08.020. Epub 2013 Aug 19.

PMID:
23968967
2.
3.

Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.

Lee SH, Chung BH, Kim SJ, Kim JH, Kim JC, Lee JY.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):320-5. doi: 10.1038/pcan.2011.22. Epub 2011 Jul 26.

PMID:
21788967
4.

Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.

Bae WJ, Bae JH, Kim SW, Chung BH, Kim JH, Kim CS, Lee HM, Lee KS, Yoo TK, Kim SI, Byun SS, Lee JY.

J Urol. 2013 Jul;190(1):180-6. doi: 10.1016/j.juro.2013.01.057. Epub 2013 Jan 25.

PMID:
23357213
5.

Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-life practice.

Bae WJ, Bae JH, Choi YS, Kim SJ, Cho HJ, Hong SH, Kim SW, Hwang TK, Lee JY.

Int Urol Nephrol. 2012 Aug;44(4):1077-84. doi: 10.1007/s11255-012-0173-5. Epub 2012 Apr 15.

PMID:
22528586
6.

Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms--a meta-analysis.

Hao N, Tian Y, Liu W, Wazir R, Wang J, Liu L, Wang K, Li H.

Urology. 2014 Mar;83(3):556-62. doi: 10.1016/j.urology.2013.10.034. Epub 2013 Dec 19. Review.

PMID:
24361007
7.

Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.

Casabé A, Roehrborn CG, Da Pozzo LF, Zepeda S, Henderson RJ, Sorsaburu S, Henneges C, Wong DG, Viktrup L.

J Urol. 2014 Mar;191(3):727-33. doi: 10.1016/j.juro.2013.09.059. Epub 2013 Oct 2.

PMID:
24096118
8.

Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.

McVary KT, Peterson A, Donatucci CF, Baygani S, Henneges C, Clouth J, Wong D, Oelke M.

J Urol. 2016 Sep;196(3):824-30. doi: 10.1016/j.juro.2016.04.062. Epub 2016 Apr 19.

PMID:
27105760
9.

Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men.

Martin S, Lange K, Haren MT, Taylor AW, Wittert G; Members of the Florey Adelaide Male Ageing Study.

J Urol. 2014 Jan;191(1):130-7. doi: 10.1016/j.juro.2013.06.018. Epub 2013 Jun 11.

PMID:
23770136
10.

Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.

Brock GB, McVary KT, Roehrborn CG, Watts S, Ni X, Viktrup L, Wong DG, Donatucci C.

J Urol. 2014 Feb;191(2):405-11. doi: 10.1016/j.juro.2013.09.057. Epub 2013 Oct 1.

PMID:
24096120
11.

α-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women.

Boyd K, Hilas O.

Ann Pharmacother. 2014 Jun;48(6):711-22. doi: 10.1177/1060028014524174. Epub 2014 Mar 10. Review.

PMID:
24615630
12.

Prevalence of lower urinary tract symptoms in middle-aged and elderly Japanese.

Osuga Y, Okamura K, Ando F, Shimokata H.

Geriatr Gerontol Int. 2013 Oct;13(4):1010-7. doi: 10.1111/ggi.12048. Epub 2013 Mar 19.

PMID:
23506541
13.

Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.

Choo MS, Song M, Kim JH, Lee KS, Kim JC, Kim SW, Yang SK, Lee JG, Lee JZ, Kim DK, Park WH, Kim KD, Na YG, Kwon DD, Paick JS.

Urology. 2014 Apr;83(4):875-81. doi: 10.1016/j.urology.2013.11.013. Epub 2014 Feb 12.

PMID:
24529580
14.

Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.

Fujimura T, Kume H, Nishimatsu H, Sugihara T, Nomiya A, Tsurumaki Y, Miyazaki H, Suzuki M, Fukuhara H, Enomoto Y, Homma Y.

BJU Int. 2012 May;109(10):1512-6. doi: 10.1111/j.1464-410X.2011.10445.x. Epub 2011 Aug 26.

15.

Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study.

Yucel S, Akkaya E, Guntekin E, Kukul E, Akman S, Melikoglu M, Baykara M.

J Urol. 2005 Oct;174(4 Pt 2):1612-5; discussion 1615.

PMID:
16148665
16.

Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.

van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, Traudtner K, Drake MJ; NEPTUNE Study Group.

Eur Urol. 2013 Dec;64(6):1003-12. doi: 10.1016/j.eururo.2013.07.034. Epub 2013 Aug 3.

18.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
19.

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.

Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z.

BJU Int. 2012 Jun;109(12):1831-40. doi: 10.1111/j.1464-410X.2011.10624.x. Epub 2011 Oct 3.

20.

Male lower urinary tract symptoms: how do symptoms guide our choice of treatment?

Gravas S, Melekos MD.

Curr Opin Urol. 2009 Jan;19(1):49-54. doi: 10.1097/MOU.0b013e32831505fe. Review.

PMID:
19057216

Supplemental Content

Support Center